The PDUFA date for the FDA's review of The Medicines Company's (MDCO +0.3%) Biologics License Application (BLA) for its hemostatic agent, Fibrocaps, is January 31. Since this is Saturday, the agency may announce its decision on Friday, January 30. ... Seeking Alpha, 16 hours ago
PDUFA date approaches for Zohydro sNDA - Seeking Alpha, 16 hours ago
PDUFA approaches for NPS Pharma's Natpara - Seeking Alpha, 6 days ago
1 images for "pdufa"
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP ) is gaining interest ahead of the company's Prescription Drug User Fee Act (PDUFA) decision on January 24, 2014. On Monday, the Wall Street Journal reported that Goldman Sachs Group Inc (NYSE: GS ) began ...Yahoo! Finance, 3 weeks ago Shire (SHP LN): Pipeline to deliver 2015 catalysts; PT +17% to 5500p European Pharmaceutical Review, 1 week ago Shire's Takeover of NPS Pharmaceuticals: What Wall Street's Saying TheStreet.com, 2 weeks ago UPDATE: Jefferies Raises Price Target On NPS Pharmaceuticals Ahead Of Acquisition By Shire Benzinga.com, 2 weeks ago
More from: Stock Nod, Stock Nod...and 58 other sources
Actavis and Gedeon discloses USFDA receipt of Cariprazine NDA resubmission for schizophrenia and manic or mixed episodes in bipolar I disorder
Pharmaceutical company Actavis The companies expect cariprazine's Prescription Drug User Fee Act (PDUFA) date to be in the second quarter of 2015. Cariprazine, which is an investigational drug, is an atypical antipsychotic for the treatment of ...BusinessWeek, 3 weeks ago Hungary Richter and Actavis announce FDA receipt of NDA resubmission for Cariprazine TeleTrader.com, 3 weeks ago Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine 4 Traders, 2 weeks ago Actavis Announces FDA Receipt Of NDA Resubmission For Cariprazine Pharmacy Choice, 3 weeks ago
To screen ETFs by asset class, performance, yield and more, check out the ETF Hub.Seeking Alpha, 3 weeks ago
REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of October 21, 2015Drugs.com, 2 days ago Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension Benzinga.com, 3 weeks ago Relypsa, Inc. Announces Assignment Of October 21, 2015 PDUFA Date For New Drug Application For Patiromer For Oral Suspension BioSpace, 3 weeks ago
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, ...BioSpace, 5 days ago
Regeneron Pharmaceuticals, Inc. and Sanofi have received the FDA acceptance for priority review of the biologics license application, or BLA, for Praluent, or alirocumab, which is intended for the treatment of patients with hypercholesterolemia.Individual.com, 3 hours ago Sanofi and Regeneron's Praluent BLA gains priority review from US FDA26-01-2015 Pharma Letter, 1 day ago FDA accepts for priority review Sanofi and Regeneron's BLA for hypercholesterolemia drug Praluent Pharmaceutical Business Review, 2 days ago Amgen Leapfrogged In Race For New Cholesterol Drug Forbes.com, 2 days ago
Operator Good evening, ladies and gentlemen, and thank you for joining the Vertex Pharmaceuticals Incorporated Fourth Quarter 2014 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now ...Seeking Alpha, 6 hours ago Vertex Pharma Expects 2015 Kalydeco Revenues Of $560 Mln To $580 Mln In 2015 RTTNews.com, 2 weeks ago Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis BusinessWeek, 2 weeks ago VERTEX PHARMACEUTICALS : Pharma Expects 2015 Kalydeco Revenues Of $560 Mln To $580 Mln In 2015 4 Traders, 2 weeks ago
Summary INCR offers a profitable service in a really hard to execute space. INCR has a growing-more-solid balance sheet, now profitable operations and free cash flow generation. Buy INCR immediately, as the shares are poised to move higher over ...Seeking Alpha, 11 hours ago
Roche Holding Ltd. ( OTCQX:RHHBY ) Q4 2014 Earnings Conference Call January 28, 2015 10:00 AM ET Severin Schwan Good afternoon ladies and gentlemen, and welcome to our Year End briefing. 2014 was a good year for Roche, we achieved our financial ...Seeking Alpha, 11 hours ago
on your WebpageAdd Widget >Get your members hooked!